Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

A method of treating a neurodegenerative disease comprising administering to a subject in need thereof an effective amount of a compound comprising the following formula or pharmaceutically acceptable salt thereof:

• wherein X is independently selected from a C—H, C—CH3, C—CH2CH3, C—CH2CH2CH3, or CR3, wherein R3 is independently selected from a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
• L1 is a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
• R1 is hydrogen, oxo, halogen, —CY3, —CN, —SO2Cl, —SOnR10, —SOvNR7R8, —NHNH2, —ONR7R8, NHC═(O)NHNH2, —NHC═(O)NR7R8, —N(O)m, —NR7R8, —C(O)R9, —C(O)OR9, —C(O)NR7R8, —OR10, NR7SO2R10, —N(R7)C═(O)R9, —NR7C(O)—OR9, —NR7OR9, —OCY3, —OCHY2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• and
• R4 is hydrogen, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• R2 is N;
• R5 is CH, CCH3, CCF3, or CC6H5;
• and
• R6 is N, a saturated carbon, CH, CD, or C—L1—R6 wherein R6 is independently halogen, —CF3, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO2Cl, —SO3H, —SO4H, —SO2NH2, SOnR10, —SOvNR7R8, —NHNH2, —ONH2, —NHC═(O)NHNH2, —NHC═(O)NH2, —NHSO2H, —NHC═(O)H, —NHC(O)—OH, —NHOH, —ONR7R8, —NHC═(O)NHNH2, —NHC═(O)NR7R8, —N(O)m, —NR7R8, —C(O)R9, —C(O)OR9, —C(O)NR7R8, —OR10, —NR7SO2R10, —N(R7)C═(O)R9, —NR7C(O)—OR9, —NR7OR9, —OCY3, —OCHY2, —OCF3, —OCHF2, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• where R7 and R8 are bonded to the same nitrogen atom, they may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl, m and v are independently 1 or 2, n is independently an integer from 0 to 4, and Y is independently —Cl, —Br, —I, or —F;
• wherein the compound does not comprise kinetin or cytokinin

A method of treating a neurodegenerative disease comprising administering to a subject in need thereof an effective amount of a compound comprising the following formula or pharmaceutically acceptable salt thereof:

• wherein X is independently selected from a C—H, C—CH3, C—CH2CH3, C—CH2CH2CH3, or CR3, wherein R3 is independently selected from a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
• L1 is a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
• R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• and R4 is hydrogen, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
• R2 is N;
• R5 is CH, CCH3, CCF3, or CC6H5;
• and
• R6 is N;
• wherein the compound does not comprise kinetin or cytokinin